According to North Carolina-based Cornerstone Therapeutics, Chiesi Farmaceutici has offered to purchase shares of Cornerstone’s common stock for between $6.40 and $6.70 per share, to take the company private. Chiesi already owns approximately 60% of the outstanding shares of Cornerstone’s common stock. No decision has been made by Cornerstone’s board of directors at this time, the company said.
Chiesi, which markets a number of inhaled products based on its Modulite MDI technology, licensed Bethkis tobramycin inhalation solution to Cornerstone in 2012.
Read the Cornerstone press release.
